Aeterna Zentaris (AEZS +2%) gains today after saying the European Patent Office has granted its...

|By:, SA News Editor

Aeterna Zentaris (AEZS +2%) gains today after saying the European Patent Office has granted its patent for the use of the ghrelin agonist, AEZS-130, which is related to methods and kits for use in diagnosis of growth hormone deficiency in humans and animals. The patent application was filed in 2007 under the title "Methods and Kits to Diagnose Growth Hormone Deficiency", and will expire in 2027. A similar patent has already been granted in the U.S.